PPT-Sofosbuvir-Velpatasvir in Decompensated HCV Cirrhosis

ASTRAL4 Source Curry MP et al N Engl J Med 2015373261828 Treatment Naïve and Treatment Experienced Phase 3 SofosbuvirVelpatasvir in Decompensated HCV Cirrhosis ASTRAL4 Study Features. Hepatitis-2015. Orlando. , USA. July 20 - 22 2015. The Growing Epidemic in HCC from Hepatitis/NASH Cirrhosis in American Veterans. Implications and Economic burdens for the Health Care in the United States and the World!. (. Epclusa. ). Prepared by. : H. Nina Kim, MD MSc and David . Spach. , MD. Last . Updated: . July . 8, . 2016. Background and Dosing. Sofosbuvir-Velpatasvir. (. Epclusa. ). Sofosbuvir-Velpatasvir. (. SIRIUS. Phase . 2 . Treatment. . Experienced. Bourliere. M, et al. Lancet Infect Dis. . 2015;15:397-404.. Source: . Bourliere. . M, . et al. . Lancet Infect Dis. 2015;15:397-404.. Ledipasvir-Sofosbuvir in Treatment-Experienced . in DAA. -Naïve GT . 1-6 . POLARIS-2. Phase 3. . Treatment Naïve and . Treament. Experienced (DAA Naïve) . Jacobson IM, . et al. . Gastroenterology. 2017;153:113-22.. Source: Jacobson IM, et al. Gastroenterology. 2017;153:113-22.. in Genotype 3. ASTRAL-3. Phase 3. . Treatment. . Naïve & Experienced. Foster GR, . et al. . N . Engl. J Med. . 2015. ;373:2608-17.. *Published in tandem with ASTRAL-2 Trial. Source: Foster GR, . ASTRAL-2*. Phase 3. . Treatment. . Naïve & Experienced. Foster GR, . et al. . N . Engl. J Med. . 2015. ;373:2608-17.. *Published in tandem with ASTRAL-3 Trial. Source: Foster GR, . et al. N . ASTRAL-1. Phase 3. . Treatment. . Naïve & Experienced. Feld JJ, . et al. . N . Engl. J Med. . 2015. ;373:2599-607.. Source: Feld . JJ. , et al. N . Engl. J Med. . 2015. ;373:2599-607.. Sofosbuvir-Velpatasvir. treatment. Lisa M. Glass, MD. Clinical Lecturer. Division of Gastroenterology and . Hepatology. Hepatitis C Virus. Flavivirus: . RNA virus. Dengue. West Nile . Yellow Fever. Zika. Heterogeneity:. Polymerase lacks proofreading capability resulting in many mutations and significant viral diversity. Medical Director, Austin Hepatitis Center. 1. Hepatitis C & PCP’s. 2. LACK OF AWARENESS. LACK OF APPROPRIATE ACTION. Expand Quantitative Landscape Study – Oct 2013 [Gilead Sciences]. 35-50% of PCP believe HCV can be cured. About these slides. These slides give a comprehensive overview of the EASL clinical practice guidelines on the management of decompensated cirrhosis. The guidelines were first presented at the International Liver Congress 2018 and are published in the Journal of Hepatology. for 12 weeks in liver transplant recipients with genotype 1-4. Agarwal K. J . Hepatol. . 2018;69:603-7. SOF/VEL: 400/100 mg 1 . tablet. QD. Liver transplant recipients. Recurrent HCV infection after transplantation. Duke University School of Medicine. Durham, North Carolina. Treatment of Hepatitis C in Patients . With . Cirrhosis. Recorded on . 10/24/14. Disclosure. Dr. Muir has received grants and research support from . Kristen M. Marks, MD. Assistant Professor. Weill Cornell Medical College . New York, New York. Financial Relationships With Commercial Entities. Dr Marks was awarded research grants, paid to her institution, from Bristol-Myers Squibb, Gilead Sciences, . SOLAR-2. Source: . Manns. M, et al. Lancet Infect Dis. 2016;16:685-97.. Treatment Naïve and Treatment Experienced, Phase 2. Ledipasvir-Sofosbuvir + Ribavirin in Advanced Liver Disease. SOLAR-2: Features.